ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vanda To Pay $100m For Rights To MS The
ScripJazz Pharmaceuticals plc has acquired near-global rights to a promising narcolepsy candidate from Japan’s Sumitomo Pharmaceuticals Europe Ltd. , paying $50m upfront at a time when some of its bigges
ScripInitial public offerings may have gotten off to a slow start with only three IPOs in January, but 10 drug developers went public in the US between 3 and 5 February raising a total of $1.9bn, including
ScripThe progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer